logo-loader

Avacta enters significant partnership with OncoSec Medical

Published: 10:45 22 Jan 2018 GMT

Alastair smith, chief executive of Avacta Group Plc’s (LON:AVCT), tells Proactive that interest in their Affimer technology continues to grow following the announcement of another collaboration agreement - this time with OncoSec Medical Inc (NASDAQ:ONCS).

OncoSec has developed a gene delivery technology called ImmunoPulse which it wants to use to deliver Affimers - including Avacta’s PD-L1 inhibitor - into tumour cells and other tissues.

The companies plan to then demonstrate efficacy of the Affimers in a relevant in vivo tumour model.

Caledonia Mining tackles 2023 challenges with optimism for 2024 as it...

Caledonia Mining Corporation PLC (AIM:CMCL, NYSE-A:CMCL) chief executive Mark Learmonth tells Proactive's Stephen Gunnion the company faced a challenging 2023, primarily due to poor production in the first half of the year at its core asset, the Blanket Mine in Zimbabwe, and an underperformance...

1 hour, 41 minutes ago